published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 14-days deathsdetailed resultsConPlas-19, 2020 0.56 [0.20; 1.57] DAWN-Plasma, 2021 0.61 [0.24; 1.55] NCT04397757, 2021 0.47 [0.04; 5.45] Sekine (PLACOVID), 2021 2.14 [0.70; 6.58] 0.82[0.42; 1.61]ConPlas-19, 2020, DAWN-Plasma, 2021, NCT04397757, 2021, Sekine (PLACOVID), 2021424%1,072moderatenot evaluable death D28detailed resultsAbdulamir, 2021 1.00 [0.20; 5.12] Abuhasira, 2021 0.72 [0.23; 2.24] AlQahtani, 2020 0.47 [0.04; 5.69] ASCOT, 2021 0.60 [0.06; 5.99] Co-CLARITY, 2021 0.92 [0.02; 50.28] COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47] COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] COLCOVID, 2021 0.88 [0.70; 1.11] CONCOR-1, 2021 1.12 [0.86; 1.46] ConPlas-19, 2020 0.49 [0.20; 1.19] COPLA-II trial, 2020 1.17 [0.72; 1.92] CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51] CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80] DAWN-Plasma, 2021 0.99 [0.52; 1.88] Declercq J (COV-AID), 2021 1.02 [0.39; 2.66] EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06] EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72] FACCT Trial, 2021 0.69 [0.28; 1.68] Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.62 [0.33; 1.17] Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36] GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50] GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86] Horby, 2021 1.01 [0.93; 1.10] Jamaati, 2021 1.19 [0.38; 3.72] Kirenga, 2021 1.25 [0.46; 3.39] Krolewiecki, 2020 0.49 [0.01; 26.05] Li, 2020 0.59 [0.22; 1.59] LIFESAVER, 2021 2.00 [0.16; 24.66] Mahajan, 2021 1.23 [0.34; 4.42] Menichetti, 2021 0.75 [0.37; 1.53] NCT04397757, 2021 0.15 [0.03; 0.75] NCT04403477 (two doses), 2021 0.53 [0.14; 2.01] NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31] NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88] NCT04528368, 2021 0.88 [0.02; 50.20] NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18] Pandit, 2021 0.95 [0.02; 50.33] PC/COVID-19, 2021 0.63 [0.11; 3.58] PERUCONPLASMA, 2021 0.36 [0.04; 3.13] Pouladzadeh, 2021 0.31 [0.01; 10.20] Raman, 2021 0.49 [0.02; 15.10] RAPID (Sholzberg), 2021 0.22 [0.07; 0.67] RECOVER, 2021 1.09 [0.38; 3.13] RECOVERY, 2020 1.09 [0.97; 1.23] RECOVERY, 2022 0.87 [0.77; 0.98] RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04] RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08] RECOVERY (colchicine), 2021 1.01 [0.93; 1.10] RECOVERY (plasma), 2021 1.00 [0.93; 1.07] RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91] Rutgers, 2021 0.59 [0.33; 1.06] Sakoulas, 2020 0.29 [0.03; 3.13] Sekine (PLACOVID), 2021 1.38 [0.73; 2.62] Shahbaznejad, 2020 2.21 [0.07; 67.87] Shashi Bhushan, 2021 4.39 [0.20; 98.33] Shu, 2020 0.38 [0.02; 8.14] SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59] Tabarsi, 2020 1.10 [0.45; 2.67] Talaschian, 2021 1.56 [0.34; 7.13] Veiga, 2021 2.70 [0.92; 7.92] 0.96[0.92; 1.00]Abdulamir, 2021, Abuhasira, 2021, AlQahtani, 2020, ASCOT, 2021, Co-CLARITY, 2021, COALITION II Covid-19 Brazil (Furtado), 2020, COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, COPLA-II trial, 2020, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-ICU (Group 2), 2020, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, FACCT Trial, 2021, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Horby, 2021, Jamaati, 2021, Kirenga, 2021, Krolewiecki, 2020, Li, 2020, LIFESAVER, 2021, Mahajan, 2021, Menichetti, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04528368, 2021, NCT04577534 (COVIDSTORM), 0, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, Pouladzadeh, 2021, Raman, 2021, RAPID (Sholzberg), 2021, RECOVER, 2021, RECOVERY, 2020, RECOVERY, 2022, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, Rutgers, 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shahbaznejad, 2020, Shashi Bhushan, 2021, Shu, 2020, SOLIDARITY (WHO study) HCQ, 2020, Tabarsi, 2020, Talaschian, 2021, Veiga, 20216010%84,642moderatecritical death or transfer to ICUdetailed resultsRAPID (Sholzberg), 2021 0.70 [0.44; 1.12] RECOVERY, 2020 1.09 [0.99; 1.20] 0.93[0.61; 1.41]RAPID (Sholzberg), 2021, RECOVERY, 2020269%5,301moderatenot evaluable deathsdetailed resultsAbd-Elsalam, 2020 1.21 [0.36; 4.12] Abdulamir, 2021 1.00 [0.20; 5.12] AlQahtani, 2020 0.47 [0.04; 5.69] ASCOT, 2021 0.60 [0.06; 5.99] Cao, 2020 0.71 [0.36; 1.40] CAPSID, 2021 0.84 [0.28; 2.50] Chen, 2020 0.56 [0.01; 30.20] Co-CLARITY, 2021 0.92 [0.02; 50.28] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.43 [0.13; 1.44] COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47] CODEX (Tomazini), 2020 0.97 [0.72; 1.31] COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] COLCOVID, 2021 0.88 [0.70; 1.11] CONCOR-1, 2021 1.02 [0.77; 1.36] ConCOVID (Gharbharan et al.), 2020 0.95 [0.20; 4.59] CONFIDENT, 2020 0.84 [0.52; 1.37] ConPlas-19, 2020 0.46 [0.19; 1.15] COP-COVID-19, 2021 0.96 [0.36; 2.56] COPLA-II trial, 2020 1.17 [0.72; 1.92] CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51] CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71] CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80] CP-COVID-19, 2021 3.20 [0.62; 16.39] Dabbous HM, 2020 0.51 [0.02; 15.41] Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25] Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92] DAWN-Plasma, 2021 0.99 [0.52; 1.88] Declercq J (COV-AID), 2021 1.02 [0.39; 2.66] DEXA-COVID19, 2020 2.00 [0.21; 18.87] Entrenas (Pilot Calcifediol), 2020 0.12 [0.01; 2.79] EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06] EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72] FACCT Trial, 2021 0.96 [0.44; 2.08] Fu, 2020 1.00 [0.02; 51.66] Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.62 [0.33; 1.17] Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36] GRECCO-19, 2020 0.21 [0.02; 1.97] GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40] GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84] Hashim A, 2020 0.48 [0.11; 1.99] Holm K, 2021 0.49 [0.08; 2.89] Horby, 2021 1.01 [0.93; 1.10] Jamaati, 2021 1.19 [0.38; 3.72] Khamis, 2020 0.83 [0.23; 2.96] Kirenga, 2021 1.25 [0.46; 3.39] Krolewiecki, 2020 0.49 [0.01; 26.05] Li, 2020 0.59 [0.22; 1.59] LIFESAVER, 2021 2.00 [0.16; 24.66] Lou (FAVIPIRAVIR), 2020 1.12 [0.02; 62.74] Lou Y, 2020 1.00 [0.02; 55.80] Mahajan, 2021 1.23 [0.34; 4.42] Menichetti, 2021 0.75 [0.37; 1.53] NCT04385199, 2021 0.75 [0.15; 3.77] NCT04397757, 2021 0.15 [0.03; 0.75] NCT04403477 (two doses), 2021 0.53 [0.14; 2.01] NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31] NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88] NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25] NCT04528368, 2021 0.88 [0.02; 50.20] NCT04542694, 2020 1.00 [0.02; 50.90] NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18] NO COVID-19 (Lyngbakken), 2020 0.96 [0.06; 15.78] NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20] Pandit, 2021 0.95 [0.02; 50.33] PC/COVID-19, 2021 0.63 [0.11; 3.58] PERUCONPLASMA, 2021 0.36 [0.04; 3.13] Pouladzadeh, 2021 0.31 [0.01; 10.20] Rahmani, 2020 0.29 [0.05; 1.56] Raman, 2021 0.49 [0.02; 15.10] RAPID (Sholzberg), 2021 0.22 [0.07; 0.67] Rasheed, 2020 0.13 [0.01; 1.09] RCT-TCZ-COVID-19, 2021 2.24 [0.20; 25.37] RECOVER, 2021 1.09 [0.38; 3.13] RECOVERY, 2020 1.09 [0.97; 1.23] RECOVERY, 2020 1.03 [0.91; 1.17] RECOVERY, 2021 0.85 [0.76; 0.95] RECOVERY, 2022 0.87 [0.77; 0.98] RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04] RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08] RECOVERY (colchicine), 2021 1.01 [0.93; 1.10] RECOVERY (plasma), 2021 1.00 [0.93; 1.07] RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91] RECOVERY dexamethasone, 2020 0.83 [0.75; 0.92] REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93] REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15] REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95] Rutgers, 2021 0.62 [0.36; 1.07] Sadeghi , 2020 0.56 [0.12; 2.56] Sakoulas, 2020 0.29 [0.03; 3.13] Sekhavati, 2020 0.49 [0.02; 14.80] Sekine (PLACOVID), 2021 1.38 [0.73; 2.62] Shashi Bhushan, 2021 4.39 [0.20; 98.33] Shu, 2020 0.38 [0.02; 8.14] Soin AS (COVINTOC), 2021 0.67 [0.29; 1.55] SOLIDARITY (lopi/rito), 2020 1.00 [0.79; 1.26] SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11] SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59] Steroids-SARI, 2020 0.91 [0.29; 2.86] Tabarsi, 2020 1.10 [0.45; 2.67] Talaschian, 2021 1.25 [0.30; 5.14] Udwadia, 2020 0.50 [0.02; 15.03] Veiga, 2021 2.70 [0.92; 7.92] Yakoot, 2020 0.38 [0.07; 2.08] 0.94[0.91; 0.97]Abd-Elsalam, 2020, Abdulamir, 2021, AlQahtani, 2020, ASCOT, 2021, Cao, 2020, CAPSID, 2021, Chen, 2020, Co-CLARITY, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, CONCOR-1, 2021, ConCOVID (Gharbharan et al.), 2020, CONFIDENT, 2020, ConPlas-19, 2020, COP-COVID-19, 2021, COPLA-II trial, 2020, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, CP-COVID-19, 2021, Dabbous HM, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, DEXA-COVID19, 2020, Entrenas (Pilot Calcifediol), 2020, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, FACCT Trial, 2021, Fu, 2020, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GRECCO-19, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Hashim A, 2020, Holm K, 2021, Horby, 2021, Jamaati, 2021, Khamis, 2020, Kirenga, 2021, Krolewiecki, 2020, Li, 2020, LIFESAVER, 2021, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, Mahajan, 2021, Menichetti, 2021, NCT04385199, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04523831 (Mahmud), 2020, NCT04528368, 2021, NCT04542694, 2020, NCT04577534 (COVIDSTORM), 0, NO COVID-19 (Lyngbakken), 2020, NOR-Solidarity (hydroxychloroquine), 2021, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, Pouladzadeh, 2021, Rahmani, 2020, Raman, 2021, RAPID (Sholzberg), 2021, Rasheed, 2020, RCT-TCZ-COVID-19, 2021, RECOVER, 2021, RECOVERY, 2020, RECOVERY, 2020, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, REMAP-CAP (tocilizumab), 2021, Rutgers, 2021, Sadeghi , 2020, Sakoulas, 2020, Sekhavati, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shu, 2020, Soin AS (COVINTOC), 2021, SOLIDARITY (lopi/rito), 2020, SOLIDARITY (remdesivir), 2020, SOLIDARITY (WHO study) HCQ, 2020, Steroids-SARI, 2020, Tabarsi, 2020, Talaschian, 2021, Udwadia, 2020, Veiga, 2021, Yakoot, 20201066%117,004moderatecritical deaths (time to event analysis only)detailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24] COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47] COLCOVID, 2021 0.88 [0.70; 1.11] CONCOR-1, 2021 1.02 [0.77; 1.36] ConPlas-19, 2020 0.46 [0.19; 1.15] CP-COVID-19, 2021 3.20 [0.62; 16.39] DAWN-Plasma, 2021 0.99 [0.52; 1.88] GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40] GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84] NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20] RECOVERY, 2020 1.09 [0.97; 1.23] RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04] RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08] REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93] Rutgers, 2021 0.62 [0.36; 1.07] SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11] SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59] Talaschian, 2021 1.25 [0.30; 5.14] 0.97[0.91; 1.03]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CP-COVID-19, 2021, DAWN-Plasma, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NOR-Solidarity (hydroxychloroquine), 2021, RECOVERY, 2020, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Rutgers, 2021, SOLIDARITY (remdesivir), 2020, SOLIDARITY (WHO study) HCQ, 2020, Talaschian, 20211920%40,923moderatelow clinical deteriorationdetailed resultsCAPSID, 2021 0.63 [0.29; 1.40] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.99 [0.57; 1.72] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.92 [0.61; 1.38] CODEX (Tomazini), 2020 0.66 [0.43; 1.02] COL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58] ConPlas-19, 2020 1.00 [0.65; 1.53] CORIMUNO-SARI-1 (non ICU), 2021 1.01 [0.48; 2.12] CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20] ELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57] ELACOI (Standard of care), 2020 0.86 [0.06; 11.36] GRECCO-19, 2020 0.11 [0.01; 1.08] Hashim A, 2020 0.40 [0.10; 1.63] Kirenga, 2021 0.91 [0.38; 2.17] Li T, 2020 0.48 [0.01; 27.44] NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84] RAPID (Sholzberg), 2021 0.69 [0.43; 1.10] RCT-TCZ-COVID-19, 2021 1.05 [0.59; 1.86] Shu, 2020 0.27 [0.01; 5.58] Soin AS (COVINTOC), 2021 0.67 [0.26; 1.77] 0.78[0.66; 0.91]CAPSID, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, ConPlas-19, 2020, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, GRECCO-19, 2020, Hashim A, 2020, Kirenga, 2021, Li T, 2020, NCT04523831 (Mahmud), 2020, RAPID (Sholzberg), 2021, RCT-TCZ-COVID-19, 2021, Shu, 2020, Soin AS (COVINTOC), 2021190%3,191moderatelow clinical improvementdetailed resultsAVIFAVIR, 2020 0.53 [0.13; 2.19] Cao, 2020 1.31 [0.94; 1.83] CAPSID, 2021 1.58 [0.71; 3.49] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.81 [0.54; 1.22] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43] COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07] ConPlas-19, 2020 0.95 [0.60; 1.52] Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] Dongsheng Wang, 2020 2.37 [0.40; 13.96] Ghandehari, 2020 1.31 [1.00; 1.71] GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74] GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49] Li, 2020 1.40 [0.79; 2.49] Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62] NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38] NCT04542694, 2020 2.10 [1.04; 4.24] Pouladzadeh, 2021 7.31 [1.62; 32.97] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06] REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15] Ruzhentsova T, 2020 1.63 [1.14; 2.34] Sekine (PLACOVID), 2021 0.94 [0.74; 1.19] Shashi Bhushan, 2021 0.68 [0.21; 2.20] Shu, 2020 10.27 [1.17; 90.18] Udwadia, 2020 1.75 [1.10; 2.79] 1.26[1.07; 1.49]AVIFAVIR, 2020, Cao, 2020, CAPSID, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, ConPlas-19, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Dongsheng Wang, 2020, Ghandehari, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Li, 2020, Lou (FAVIPIRAVIR), 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pouladzadeh, 2021, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (tocilizumab), 2021, Ruzhentsova T, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shu, 2020, Udwadia, 20202459%5,065moderatelow clinical improvement (14-day)detailed resultsAVIFAVIR, 2020 0.53 [0.13; 2.19] Cao, 2020 1.94 [1.09; 3.48] Chen, 2020 0.56 [0.13; 2.48] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.01 [0.58; 1.76] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43] COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07] GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47] GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44] Li, 2020 2.27 [0.90; 5.72] Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62] Lou Y, 2020 1.50 [0.26; 8.82] Pandit, 2021 8.77 [0.94; 81.67] REMAP-CAP (lopinavir/ritonavir only), 2020 0.85 [0.64; 1.12] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06] Ruzhentsova T, 2020 1.28 [1.05; 1.56] Sadeghi , 2020 3.63 [1.02; 12.93] Shashi Bhushan, 2021 0.68 [0.21; 2.20] Shu, 2020 10.27 [1.17; 90.18] 1.13[0.91; 1.40]AVIFAVIR, 2020, Cao, 2020, Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Li, 2020, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, Pandit, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Ruzhentsova T, 2020, Sadeghi , 2020, Shashi Bhushan, 2021, Shu, 20201956%4,445moderatelow clinical improvement (21-day)detailed resultsLi T, 2020 2.09 [0.04; 119.96] 2.09[0.04; 119.96]Li T, 202010%18NAnot evaluable clinical improvement (28-day)detailed resultsAbuhasira, 2021 1.70 [0.52; 5.49] Cao, 2020 1.59 [0.84; 3.03] COALITION II Covid-19 Brazil (Furtado), 2020 0.70 [0.47; 1.04] GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42] GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17] Li, 2020 1.42 [0.65; 3.10] Pouladzadeh, 2021 7.31 [1.62; 32.97] Ruzhentsova T, 2020 1.11 [0.96; 1.29] Sekine (PLACOVID), 2021 0.94 [0.74; 1.19] Shu, 2020 3.68 [0.18; 75.54] Udwadia, 2020 1.75 [1.10; 2.79] 1.30[1.03; 1.64]Abuhasira, 2021, Cao, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Li, 2020, Pouladzadeh, 2021, Ruzhentsova T, 2020, Sekine (PLACOVID), 2021, Shu, 2020, Udwadia, 20201159%2,126moderatecritical clinical improvement (7-day)detailed resultsCao, 2020 3.16 [0.62; 16.06] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.89 [0.59; 1.35] COALITION II Covid-19 Brazil (Furtado), 2020 0.94 [0.63; 1.40] GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53] GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09] Li, 2020 0.98 [0.27; 3.58] Lou Y, 2020 1.00 [0.05; 18.57] NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93] NCT04542694, 2020 2.10 [1.04; 4.24] Ruzhentsova T, 2020 1.50 [1.02; 2.21] Shashi Bhushan, 2021 1.91 [1.03; 3.53] Shu, 2020 6.72 [1.50; 30.07] 1.39[1.10; 1.75]Cao, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Li, 2020, Lou Y, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ruzhentsova T, 2020, Shashi Bhushan, 2021, Shu, 20201246%2,828moderatelow clinical improvement (time to event analysis only)detailed resultsAbuhasira, 2021 1.22 [0.70; 2.14] Cao, 2020 1.31 [0.94; 1.83] ConPlas-19, 2020 0.95 [0.60; 1.52] Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18] FACCT Trial, 2021 0.85 [0.62; 1.16] GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44] GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42] Li, 2020 1.40 [0.79; 2.49] NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38] Rahmani, 2020 3.41 [1.33; 8.73] Ruzhentsova T, 2020 1.63 [1.14; 2.34] Udwadia, 2020 1.75 [1.10; 2.79] 1.31[1.12; 1.53]Abuhasira, 2021, Cao, 2020, ConPlas-19, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Li, 2020, NCT04523831 (Mahmud), 2020, Rahmani, 2020, Ruzhentsova T, 2020, Udwadia, 20201344%2,162moderatecritical death or ventilationdetailed resultsCOLCOVID, 2021 0.83 [0.67; 1.02] CONCOR-1, 2021 1.16 [0.94; 1.43] ConPlas-19, 2020 0.94 [0.86; 1.02] CORIMUNO-SARI-1 (non ICU), 2021 1.12 [0.56; 2.22] CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31] DAWN-Plasma, 2021 1.01 [0.64; 1.59] Menichetti, 2021 0.88 [0.59; 1.32] RAPID (Sholzberg), 2021 0.59 [0.34; 1.02] RECOVERY, 2020 1.14 [1.03; 1.27] RECOVERY, 2021 0.85 [0.78; 0.93] RECOVERY, 2022 0.90 [0.81; 0.99] RECOVERY (AZI, Horby), 2020 0.95 [0.87; 1.03] RECOVERY (colchicine), 2021 1.02 [0.96; 1.09] RECOVERY (plasma), 2021 0.99 [0.93; 1.05] RECOVERY (REGN-COV2), 2021 0.83 [0.75; 0.92] RECOVERY dexamethasone, 2020 0.92 [0.84; 1.01] Rutgers, 2021 0.65 [0.43; 0.99] SOLIDARITY (remdesivir), 2020 0.97 [0.85; 1.10] SOLIDARITY (WHO study) HCQ, 2020 1.11 [0.87; 1.42] Veiga, 2021 1.54 [0.65; 3.63] 0.95[0.90; 1.00]COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, DAWN-Plasma, 2021, Menichetti, 2021, RAPID (Sholzberg), 2021, RECOVERY, 2020, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, Rutgers, 2021, SOLIDARITY (remdesivir), 2020, SOLIDARITY (WHO study) HCQ, 2020, Veiga, 20212061%65,446moderatelow hospital dischargedetailed resultsConPlas-19, 2020 1.02 [0.82; 1.28] DAWN-Plasma, 2021 1.06 [0.87; 1.30] FACCT Trial, 2021 0.88 [0.64; 1.21] Li T, 2020 10.00 [1.03; 97.50] Rahmani, 2020 3.44 [0.64; 18.49] RECOVERY, 2020 0.98 [0.91; 1.05] RECOVERY (Aspirin), 2022 1.06 [1.02; 1.10] RECOVERY (AZI, Horby), 2020 1.04 [0.98; 1.10] RECOVERY (colchicine), 2021 0.98 [0.94; 1.03] RECOVERY (plasma), 2021 0.99 [0.92; 1.07] RECOVERY (REGN-COV2), 2021 1.19 [1.08; 1.31] RECOVERY dexamethasone, 2020 1.10 [1.03; 1.17] REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.69; 1.00] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.43; 0.92] Udwadia, 2020 1.41 [0.97; 2.03] 1.03[0.98; 1.08]ConPlas-19, 2020, DAWN-Plasma, 2021, FACCT Trial, 2021, Li T, 2020, Rahmani, 2020, RECOVERY, 2020, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Udwadia, 20201568%62,544moderatelow mechanical ventilationdetailed resultsAbuhasira, 2021 1.62 [0.41; 6.39] AlQahtani, 2020 0.67 [0.22; 2.02] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.77 [0.81; 3.87] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.54 [0.70; 3.37] COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] COPLA-II trial, 2020 0.58 [0.37; 0.92] Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67] Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67] Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.70 [0.52; 0.95] Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.85 [0.68; 1.06] GRECCO-19, 2020 0.17 [0.02; 1.48] GS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30] GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45] Holm K, 2021 0.39 [0.01; 12.68] Jamaati, 2021 1.38 [0.45; 4.20] Li T, 2020 0.40 [0.04; 3.90] Lou Y, 2020 2.11 [0.06; 70.98] Mahajan, 2021 2.27 [0.39; 13.27] NCT04397757, 2021 0.41 [0.13; 1.35] Rahmani, 2020 0.29 [0.05; 1.56] RAPID (Sholzberg), 2021 0.70 [0.32; 1.54] RCT-TCZ-COVID-19, 2021 1.36 [0.39; 4.69] RECOVERY, 2022 0.87 [0.74; 1.02] RECOVERY (AZI, Horby), 2020 0.92 [0.79; 1.07] RECOVERY (colchicine), 2021 1.04 [0.93; 1.16] RECOVERY (plasma), 2021 0.98 [0.88; 1.09] RECOVERY dexamethasone, 2020 0.77 [0.62; 0.95] Rutgers, 2021 0.65 [0.35; 1.24] Sadeghi , 2020 0.37 [0.09; 1.58] Sakoulas, 2020 0.19 [0.03; 1.11] Sekhavati, 2020 0.16 [0.01; 3.19] Shahbaznejad, 2020 2.24 [0.19; 25.88] Shu, 2020 0.59 [0.02; 14.04] Soin AS (COVINTOC), 2021 1.05 [0.46; 2.38] SOLIDARITY (remdesivir), 2020 1.04 [0.87; 1.23] Tabarsi, 2020 1.49 [0.59; 3.78] Udwadia, 2020 0.06 [0.01; 0.83] Yakoot, 2020 0.38 [0.07; 2.08] 0.89[0.82; 0.97]Abuhasira, 2021, AlQahtani, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, COPLA-II trial, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GRECCO-19, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Holm K, 2021, Jamaati, 2021, Li T, 2020, Lou Y, 2020, Mahajan, 2021, NCT04397757, 2021, Rahmani, 2020, RAPID (Sholzberg), 2021, RCT-TCZ-COVID-19, 2021, RECOVERY, 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY dexamethasone, 2020, Rutgers, 2021, Sadeghi , 2020, Sakoulas, 2020, Sekhavati, 2020, Shahbaznejad, 2020, Shu, 2020, Soin AS (COVINTOC), 2021, SOLIDARITY (remdesivir), 2020, Tabarsi, 2020, Udwadia, 2020, Yakoot, 20203827%52,582moderatecritical mechanical ventilation (time to event analysis only)detailed resultsCP-COVID-19, 2021 0.66 [0.25; 1.72] DAWN-Plasma, 2021 1.08 [0.65; 1.80] Udwadia, 2020 0.06 [0.01; 0.83] 0.65[0.25; 1.70]CP-COVID-19, 2021, DAWN-Plasma, 2021, Udwadia, 2020360%597moderatenot evaluable radiologic improvement (14-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28] ELACOI (Standard of care), 2020 0.18 [0.01; 3.99] Jamaati, 2021 4.89 [1.15; 20.79] Rashad (CLARI vs SoC), 2021 2.87 [1.56; 5.28] Rashad A (AZI vs SoC), 2021 1.64 [0.94; 2.88] Tabarsi, 2020 2.33 [0.45; 12.00] 2.13[1.30; 3.50]ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Jamaati, 2021, Rashad (CLARI vs SoC), 2021, Rashad A (AZI vs SoC), 2021, Tabarsi, 2020621%584moderatenot evaluable radiologic improvement (7-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09] ELACOI (Standard of care), 2020 0.08 [0.00; 1.71] 0.09[0.01; 0.78]ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 202020%46moderatenot evaluable viral clearance detailed resultsAVIFAVIR, 2020 3.89 [1.23; 12.29] CP-COVID-19, 2021 1.12 [0.16; 7.84] Dabbous HM, 2020 1.33 [0.60; 2.93] ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76] ELACOI (Standard of care), 2020 2.80 [0.31; 25.53] Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75] NCT04542694, 2020 13.03 [2.96; 57.24] Pandit, 2021 2.33 [0.55; 9.83] Raman, 2021 36.42 [10.85; 122.18] Ruzhentsova T, 2020 1.28 [0.92; 1.79] Salman, 2020 1.00 [0.02; 53.89] Shashi Bhushan, 2021 2.77 [1.44; 5.32] Udwadia, 2020 1.37 [0.94; 1.98] 2.48[1.47; 4.17]AVIFAVIR, 2020, CP-COVID-19, 2021, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Lou (FAVIPIRAVIR), 2020, NCT04542694, 2020, Pandit, 2021, Raman, 2021, Ruzhentsova T, 2020, Salman, 2020, Shashi Bhushan, 2021, Udwadia, 20201372%1,258moderatelow viral clearance (time to event analysis only)detailed resultsRuzhentsova T, 2020 1.28 [0.92; 1.79] Udwadia, 2020 1.37 [0.94; 1.98] 1.32[1.03; 1.69]Ruzhentsova T, 2020, Udwadia, 202020%318moderatenot evaluable viral clearance by day 14detailed resultsAVIFAVIR, 2020 3.08 [0.62; 15.39] Chen, 2020 1.42 [0.26; 7.76] CP-COVID-19, 2021 1.51 [0.33; 6.94] ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76] ELACOI (Standard of care), 2020 2.80 [0.31; 25.53] Kirenga, 2021 0.95 [0.76; 1.19] Li T, 2020 1.00 [0.03; 34.67] Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75] Lou Y, 2020 0.12 [0.01; 2.86] Pandit, 2021 10.23 [1.12; 93.35] Raman, 2021 36.42 [10.85; 122.18] Ruzhentsova T, 2020 0.99 [0.93; 1.06] Shashi Bhushan, 2021 0.00 [0.00; 0.01] 0.97[0.48; 1.93]AVIFAVIR, 2020, Chen, 2020, CP-COVID-19, 2021, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Kirenga, 2021, Li T, 2020, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, Pandit, 2021, Raman, 2021, Ruzhentsova T, 2020, Shashi Bhushan, 20211393%2,053moderatelow viral clearance by day 7detailed resultsAVIFAVIR, 2020 3.89 [1.23; 12.29] Dabbous HM, 2020 1.33 [0.60; 2.93] ELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91] ELACOI (Standard of care), 2020 0.67 [0.10; 4.58] Kirenga, 2021 0.87 [0.65; 1.16] Lou Y, 2020 1.50 [0.26; 8.82] Pandit, 2021 2.33 [0.55; 9.83] Ruzhentsova T, 2020 1.05 [0.92; 1.20] Salman, 2020 1.00 [0.02; 53.89] Shashi Bhushan, 2021 2.77 [1.44; 5.32] 1.27[0.92; 1.76]AVIFAVIR, 2020, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Kirenga, 2021, Lou Y, 2020, Pandit, 2021, Ruzhentsova T, 2020, Salman, 2020, Shashi Bhushan, 20211052%837moderatelow ICU admissiondetailed resultsAbd-Elsalam, 2020 0.83 [0.35; 1.95] Abuhasira, 2021 1.96 [0.51; 7.52] COL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69] CP-COVID-19, 2021 0.82 [0.35; 1.91] Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71] Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94] Entrenas (Pilot Calcifediol), 2020 0.03 [0.00; 0.27] FACCT Trial, 2021 1.42 [0.79; 2.55] Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.87 [0.69; 1.10] Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.99 [0.56; 1.75] Khamis, 2020 1.03 [0.35; 3.03] Lou (FAVIPIRAVIR), 2020 5.43 [0.21; 139.89] Lou Y, 2020 2.11 [0.06; 70.98] Rahmani, 2020 0.37 [0.14; 1.00] RAPID (Sholzberg), 2021 0.79 [0.48; 1.30] Rutgers, 2021 0.96 [0.55; 1.68] Sekhavati, 2020 0.25 [0.05; 1.28] Soin AS (COVINTOC), 2021 1.33 [0.67; 2.64] Tabarsi, 2020 0.56 [0.18; 1.74] Yakoot, 2020 0.38 [0.07; 2.08] 0.86[0.69; 1.06]Abd-Elsalam, 2020, Abuhasira, 2021, COL-COVID (Pascual-Figal), 2021, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Entrenas (Pilot Calcifediol), 2020, FACCT Trial, 2021, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Khamis, 2020, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, Rahmani, 2020, RAPID (Sholzberg), 2021, Rutgers, 2021, Sekhavati, 2020, Soin AS (COVINTOC), 2021, Tabarsi, 2020, Yakoot, 20202022%2,800moderatelow recoverydetailed resultsAbdulamir, 2021 1.00 [0.20; 5.12] GS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37] GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45] Talaschian, 2021 0.64 [0.14; 2.92] Yakoot, 2020 1.60 [1.00; 2.55] 1.17[1.02; 1.35]Abdulamir, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Talaschian, 2021, Yakoot, 202050%1,071moderatenot evaluable cardiac arrestdetailed resultsSOLIDARITY (WHO study) HCQ, 2020 1.92 [0.35; 10.49] 1.92[0.35; 10.49]SOLIDARITY (WHO study) HCQ, 202010%1,853NAnot evaluable related SAE (TRSAE)detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 1.24 [0.50; 3.11] 1.24[0.50; 3.11]COALITION II Covid-19 Brazil (Furtado), 202010%439NAnot evaluable serious adverse eventsdetailed resultsCao, 2020 0.52 [0.27; 1.01] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.87 [0.36; 9.75] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.02 [0.20; 5.10] COALITION II Covid-19 Brazil (Furtado), 2020 1.20 [0.82; 1.77] CODEX (Tomazini), 2020 0.53 [0.17; 1.62] COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] CONCOR-1, 2021 1.27 [1.02; 1.58] ConPlas-19, 2020 0.89 [0.43; 1.86] Dongsheng Wang, 2020 0.91 [0.02; 47.31] GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23] GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14] Krolewiecki, 2020 1.00 [0.03; 31.59] Lou Y, 2020 2.25 [0.38; 13.47] NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58] NCT04542694, 2020 6.15 [0.30; 124.49] Pandit, 2021 0.95 [0.02; 50.33] Raman, 2021 0.49 [0.02; 15.10] REMAP-CAP (lopinavir/ritonavir only), 2020 1.57 [0.70; 3.49] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.97 [0.22; 4.33] REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46] Ruzhentsova T, 2020 2.06 [0.09; 46.40] Sadeghi , 2020 1.00 [0.02; 51.94] Sekine (PLACOVID), 2021 1.14 [0.88; 1.48] Soin AS (COVINTOC), 2021 0.97 [0.44; 2.13] Talaschian, 2021 7.93 [0.37; 171.38] Udwadia, 2020 1.03 [0.02; 52.48] Veiga, 2021 1.66 [0.60; 4.59] Yakoot, 2020 1.02 [0.02; 52.72] 1.14[1.01; 1.30]Cao, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, CONCOR-1, 2021, ConPlas-19, 2020, Dongsheng Wang, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Krolewiecki, 2020, Lou Y, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pandit, 2021, Raman, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, Ruzhentsova T, 2020, Sadeghi , 2020, Sekine (PLACOVID), 2021, Soin AS (COVINTOC), 2021, Talaschian, 2021, Udwadia, 2020, Veiga, 2021, Yakoot, 2020280%8,734moderatelow superinfectiondetailed resultsRahmani, 2020 0.18 [0.02; 1.59] 0.18[0.02; 1.59]Rahmani, 202010%66NAnot evaluable acute kidney injury detailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.18 [0.44; 3.18] 1.18[0.44; 3.18]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%345NAnot evaluable adverse eventsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.22 [1.43; 3.44] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.21 [0.82; 1.78] COL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08] Dongsheng Wang, 2020 9.64 [2.76; 33.75] GS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42] GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80] Kirenga, 2021 1.13 [0.50; 2.58] Krolewiecki, 2020 1.53 [0.42; 5.58] NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77] NCT04542694, 2020 1.00 [0.54; 1.85] Pandit, 2021 1.68 [0.47; 5.97] Raman, 2021 1.36 [0.56; 3.30] RECOVERY, 2020 1.36 [0.98; 1.90] Ruzhentsova T, 2020 1.90 [0.96; 3.80] Sakoulas, 2020 1.00 [0.02; 53.46] Sekine (PLACOVID), 2021 1.08 [0.85; 1.38] Shu, 2020 2.48 [0.05; 132.54] Soin AS (COVINTOC), 2021 1.50 [0.78; 2.87] Udwadia, 2020 6.36 [2.43; 16.65] Veiga, 2021 1.65 [0.81; 3.37] 1.53[1.26; 1.85]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, Dongsheng Wang, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Kirenga, 2021, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pandit, 2021, Raman, 2021, RECOVERY, 2020, Ruzhentsova T, 2020, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shu, 2020, Soin AS (COVINTOC), 2021, Udwadia, 2020, Veiga, 20212144%8,592moderatecritical arrhythmiadetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.24 [0.23; 21.69] RECOVERY (AZI, Horby), 2020 0.90 [0.71; 1.15] Sekhavati, 2020 0.98 [0.02; 50.38] 0.91[0.72; 1.15]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, RECOVERY (AZI, Horby), 2020, Sekhavati, 202030%8,290moderatenot evaluable elevated liver enzymesdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 3.48 [1.40; 8.64] 3.48[1.40; 8.64]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%416NAnot evaluable long QTdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 9.79 [1.27; 75.50] COALITION II Covid-19 Brazil (Furtado), 2020 0.90 [0.56; 1.43] 2.39[0.24; 23.87]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION II Covid-19 Brazil (Furtado), 2020280%613moderatenot evaluable renal impairmentdetailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.35 [0.47; 3.86] COALITION II Covid-19 Brazil (Furtado), 2020 1.44 [0.99; 2.11] 1.43[1.00; 2.05]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 202020%770moderatenot evaluable Thromboembolic eventsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.89 [0.31; 2.55] 0.89[0.31; 2.55]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%345NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-05-12 00:43 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290